Navigation Links
Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints

DENVER--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its post-clearance marketing study comparing EpiCeram's(TM) efficacy to that of Cutivate(R) cream, a mid-strength topical steroid in the treatment of moderate-to-severe atopic dermatitis (AD).

The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate(R) and 54 patients receiving treatment with EpiCeram(TM). After 28 days of treatment, the study demonstrated that: -0-

       Both EpiCeram(TM) and Cutivate(R) produced significant

       improvement in patients' conditions after 28 days of treatment;


       There were no statistically significant differences between the

       groups treated with EpiCeram(TM) compared to those treated with

       Cutivate(R) as measured by the SCORAD index at Day 28 (the

       primary outcome measure) or in the percentage of patients

       assessed to be "clear or almost clear" by physician assessment

       at Day 28 (a secondary outcome measure).


       Both EpiCeram(TM) and Cutivate(R) produced significant relief

       from itching (pruritus) and improvement in sleep habits after

       28 days of treatment and that there was no statistically

       significant difference between the two treatments in these

       measures at this time point (both secondary outcome measures).

"The data from this study demonstrate that EpiCeram(TM) is effective and offers both the clinician and parents a new approach for treating atopic dermatitis without the risks often associated with long-term use of topical steroids or immunosuppressants," said Lawrence Charles Parish, M.D., Clinical Professor of Dermatology and Cutaneous Biology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, one of the study's principal investigators.

Atopi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:7/21/2014)...  An International Trade Commission (ITC) ruling issued Friday ... device, Taiwanese device manufacturer APEX continues to infringe ResMed ... ) is the innovation leader and pioneer in designing ... "Our research and development teams are ... of comfort, performance and efficacy," said David Pendarvis ...
(Date:7/21/2014)... Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... announces that the United States International Trade Commission (USITC) ... newly designed XT series continuous positive airway pressure (CPAP) ... the patent claims asserted by ResMed, one of Apex,s ... an upgraded iCH water tank to the market in ...
(Date:7/18/2014)... 2014 Hanger, Inc. (NYSE: HGR ) ... operations for the quarter ended June 30, 2014, on Tuesday, ... to discuss these results is scheduled to begin at 9:00 ... participate should call 1-877-662-6095. A replay will be available until ... ID # 44683027. About Hanger, Inc. – Built ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
(Date:7/21/2014)... iFitDress.com, a famous company of wedding dresses and special ... of 2014 glitter evening dresses . Moreover, the ... gowns. , iFitDress.com is one of the most loved ... in the recent years, not just because of its ... amicable services offered on its website. , The ...
(Date:7/21/2014)... MA (PRWEB) July 21, 2014 What ... extramarital affair have in common? You can find them ... Heart! The novel's main character, Miranda, lives on Martha’s ... meets Clay, a wealthy New Yorker, and becomes entangled ... of the Heart challenges readers to think about what ...
(Date:7/21/2014)... July 21, 2014 Executives from ... specializing in private healthcare practices, will participate in ... They will be showcasing their state-of-the-art capabilities and ... practices all over the United States as the ... continues to increase. Advice Media’s presence at IACA ...
(Date:7/21/2014)... 2014The Associated Press-NORC Center for Public Affairs Research has ... public,s opinions about what it means to be a ... survey, funded by the Robert Wood Johnson Foundation, sheds ... of their health care and doctors, as well as ... care decisions. The survey produces new and actionable data ...
(Date:7/21/2014)... 2014 (HealthDay News) -- Good parenting and life ... from low-income families, a new study suggests. ... and can lead to a number of illnesses, ... problems in both childhood and adulthood involve excessive ... heart disease, allergies and some cancers," study author ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: 2014 Glitter Evening Dresses For Worldwide Clients 2Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2Health News:Life Skills, Parenting Classes May Cut Inflammation in Poor Kids 2
... past have argued about the implications of Hormone Replacement Therapy ... A new study, however, has gone further to show that ... developing breast cancer// if they consumed alcoholic beverages. ,The ... pattern and on whether they were on HRT currently or ...
... have found that people who take anti-depressants to relieve ... developing gastrointestinal bleeding. The study which was conducted over ... were compared for hospitalizations due to upper GI bleeding ... on selective serotonin reuptake inhibitors, or SSRIs, were 3.6-times ...
... by a Diabetes Research Centre in India has shown that ... had considerable improvement when they followed safe practices advised by ... doctors discovering that many patients came to the Centre with ... their lives. They decided that a little change in lifestyle ...
... called 'HERS' conducted by researchers of the University of California, ... that Hormone Replacement Therapy (HRT) may be able to reduce ... develop diabetes as well. ,The study involved some women ... had "impaired fasting glucose" - a condition with some ...
... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
... Chairman and Managing Director of Eli Lilly and Co., India, ... cut in the company's human insulin product 'Huminsulin', that its ... market by the end of this year. He added that ... use of human insulin products and the phasing out of ...
Cached Medicine News:Health News:Women on HRT should avoid alcohol 2
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: